From pumps to prevention: recent advances in the treatment of type 1 diabetes

被引：7

作者：

Sherr, Jennifer ^{[1
,2
]}

Cengiz, Eda ^{[1
,2
]}

Tamborlane, William V. ^{[1
,2
]}

机构：

[1] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA

[2] Yale Univ, Sch Med, Yale Ctr Clin Investigat, New Haven, CT 06510 USA

来源：

DRUG DISCOVERY TODAY | 2009年 / 14卷 / 19-20期

基金：

美国国家卫生研究院;

关键词：

CONTINUOUS SUBCUTANEOUS INSULIN; ANTI-CD3; MONOCLONAL-ANTIBODY; MULTIPLE DAILY INJECTIONS; RANDOMIZED CONTROLLED-TRIAL; GLUCOSE MONITORING-SYSTEM; PLACEBO-CONTROLLED TRIAL; BONE-MINERAL DENSITY; QUALITY-OF-LIFE; GLYCEMIC CONTROL; PEDIATRIC-PATIENTS;

D O I：

10.1016/j.drudis.2009.06.011

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Treatment options for pediatric patients living with type 1 diabetes mellitus (T1DM) have drastically changed over the past 30 years. Technological advances including the development of continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) have allowed for improved insulin delivery and a better understanding of blood glucose fluctuations. Manipulations of CSII and CGM will allow for the development of an artificial pancreas; initial studies of this technology will be reviewed. New medications for the treatment of T1DM have been developed, such as rapid-acting insulins. Another area of exploration is the autoimmune process that causes beta-cell destruction. Immunomodulators used for T1DM prevention and secondary intervention will be reviewed.

引用

收藏

页码：973 / 981

页数：9

相关论文

共 87 条

[1] Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody-positive relatives [J].

Achenbach, P. ;

Warncke, K. ;

Reiter, J. ;

Williams, A. J. K. ;

Ziegler, A. G. ;

Bingley, P. J. ;

Bonifacio, E. .

DIABETOLOGIA, 2006, 49 (12) :2969-2976

[2]

Ahern Jo Ann H, 2002, Pediatr Diabetes, V3, P10

[3] Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regimen using insulin glargine in type 1 diabetes [J].

Alemzadeh, R ;

Ellis, JN ;

Holzum, MK ;

Parton, EA ;

Wyatt, DT .

PEDIATRICS, 2004, 114 (01) :E91-E95

[4] INSULIN RESISTANCE OF PUBERTY - A DEFECT RESTRICTED TO PERIPHERAL GLUCOSE-METABOLISM [J].

AMIEL, SA ;

CAPRIO, S ;

SHERWIN, RS ;

PLEWE, G ;

HAYMOND, MW ;

TAMBORLANE, WV .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (02) :277-282

[5] ADA Outstanding Scientific Achievement Lecture 2004 - Thirty years of investigating the autointmune basis for type 1 diabetes - Why can't we prevent or reverse this disease? [J].

Atkinson, MA .

DIABETES, 2005, 54 (05) :1253-1263

[6] Glucagon-like peptide I improved glycemic control in type I diabetes [J].

Margaret T Behme ;

John Dupré ;

Thomas J McDonald .

BMC Endocrine Disorders, 3 (1)

[7] Feasibility and safety of insulin pump therapy in children aged 2 to 7 years with type 1 diabetes: a retrospective study [J].

Berhe, Tseghai ;

Postellon, Daniel ;

Wilson, Bruce ;

Stone, Roberta .

PEDIATRICS, 2006, 117 (06) :2132-2137

[8] Limitations of conventional methods of self-monitoring of blood glucose - Lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes [J].

Boland, E ;

Monsod, T ;

Delucia, M ;

Brandt, CA ;

Fernando, S ;

Tamborlane, WV .

DIABETES CARE, 2001, 24 (11) :1858-1862

[9] Continuous subcutaneous insulin infusion - A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes [J].

Boland, EA ;

Grey, M ;

Oesterle, A ;

Fredrickson, L ;

Tamborlane, WV .

DIABETES CARE, 1999, 22 (11) :1779-1784

[10] FACTORS ASSOCIATED WITH EARLY REMISSION OF TYPE-I DIABETES IN CHILDREN TREATED WITH CYCLOSPORINE [J].

BOUGNERES, PF ;

CAREL, JC ;

CASTANO, L ;

BOITARD, C ;

GARDIN, JP ;

LANDAIS, P ;

HORS, J ;

MIHATSCH, MJ ;

PAILLARD, M ;

CHAUSSAIN, JL ;

BACH, JF .

NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (11) :663-670

← 1 2 3 4 5 6 7 8 9 →